Status of Sentinel Lymph Node Mapping in Non–Small Cell Lung CancerShersher, David D. MD; Liptay, Michael J. MDThe Cancer Journal: January/February 2015 - Volume 21 - Issue 1 - p 17–20 doi: 10.1097/PPO.0000000000000089 Reviews Buy Abstract Author InformationAuthors Article MetricsMetrics Sentinel lymph node mapping has become the standard of care in melanoma and breast cancer, contributing to marked improvements in accurate staging and targeted treatment, while decreasing morbidity of aggressive nodal bed dissections. Since 1999, several groups have proposed similar mapping in lung cancer models with mixed success. This article reviews the research up to date and discusses opportunities to improve accuracy of sentinel lymph node biopsy in non–small cell lung cancer. From the Thoracic Oncology Program, Rush University Medical Center, Chicago, IL. Conflicts of Interest and Source of Funding: M.J.L. is consultant to Covidien and Neomend. For D.D.S., none were declared. Reprints: Michael J. Liptay, MD, Division of Thoracic Surgery, Rush University Medical Center, Rush Professional Office Bldg, 1725 W Harrison St, Suite 774, Chicago, IL 60612. E-mail: email@example.com. Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.